Acceleron Pharma Inc (XLRN)

30.98
3.00 8.80
NASDAQ : Health Care
Prev Close 33.98
Open 33.48
Day Low/High 30.61 / 33.95
52 Wk Low/High 20.00 / 50.86
Volume 712.88K
Avg Volume 354.60K
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 1.32B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Preliminary Results From An Investigator Initiated Phase 2 Study Of Sotatercept In Myelofibrosis At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with...

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

Acceleron, Celgene Seek to Replace Entrenched Anti-Anemia Drugs in MDS Treatment

While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma To Host Conference Call And Webcast To Review Data Presented At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results

Acceleron Pharma Reports Third Quarter 2016 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today provided a...

RSI Alert: Acceleron Pharma (XLRN) Now Oversold

RSI Alert: Acceleron Pharma (XLRN) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Announces New Data Presentations At The 58th American Society Of Hematology Annual Meeting And Exposition

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron To Present At Credit Suisse Healthcare Conference Monday, November 7, 2016

Acceleron To Present At Credit Suisse Healthcare Conference Monday, November 7, 2016

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma To Webcast Conference Call Of Third Quarter 2016 Financial Results On November 3, 2016

Acceleron Pharma To Webcast Conference Call Of Third Quarter 2016 Financial Results On November 3, 2016

Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron To Host Educational Webcast On Facioscapulohumeral Muscular Dystrophy (FSHD) With Leading Researcher And Provide Overview Of ACE-083 Phase 2 Trial

Acceleron To Host Educational Webcast On Facioscapulohumeral Muscular Dystrophy (FSHD) With Leading Researcher And Provide Overview Of ACE-083 Phase 2 Trial

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Announces Retirement Of John Knopf As President And CEO; Habib Dable Named As Successor

Acceleron Announces Retirement Of John Knopf As President And CEO; Habib Dable Named As Successor

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced the...

Acceleron To Participate In Three Healthcare Investor Conferences In September

Acceleron To Participate In Three Healthcare Investor Conferences In September

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that...

Acceleron Pharma Reports Second Quarter 2016 Financial And Operational Results

Acceleron Pharma Reports Second Quarter 2016 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of highly innovative therapeutics to treat serious and rare diseases, today...

Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016

Acceleron Pharma To Webcast Conference Call Of Second Quarter 2016 Financial Results On August 4, 2016

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors

Acceleron Pharma Appoints Thomas McCourt To Its Board Of Directors

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases

Acceleron Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today

Acceleron Pharma (XLRN) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "perilous reversal" (up big yesterday but down big today) candidate

Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock

Acceleron Pharma (XLRN) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease

Acceleron Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.

Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock

Acceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Acceleron Pharma (XLRN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ: CELG) today announced that preliminary results will be presented from an ongoing long-term Phase 2 extension study in patients with beta-thalassemia...

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association

Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ: CELG), today announced preliminary results from an ongoing long-term Phase 2 extension study with luspatercept in patients with lower risk myelodysplastic...

Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma To Participate In Two Healthcare Investor Conferences In June

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association

Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...

Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial And Operational Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and...